Pradefovir Treatment in patients with chronic Hepatitis B: Week 24 results from a Multicenter, Double-Blind, randomized, noninferiority, phase 2 trial
In a conversation with Pharmaceutical Executive, Jay Bregman, CEO and co-founder of Andel, discusses the potential impact of the FDA's increased scrutiny on non-FDA approved GLP-1 products, particularly on the competitive landscape for obesity and diabetes therapies
The role of NRP-1 still needs to be further explored
Many German online pharmacies stopped delivering to U.K
Quick Answer: Lightheadedness with tirzepatide typically occurs indirectly through hypoglycemia when combined with other diabetes medications, dehydration from gastrointestinal side effects, or orthostatic hypotension related to weight loss